The cysteinyl leukotrienes (CysLTs) are important mediators of human asthma. Pharmacologic and clinical studies show that the CysLTs exert most of their bronchoconstrictive and proinflammatory effects through activation of a putative, 7-transmembrane domain, G-protein-coupled receptor, the CysLT 1 receptor. The initial molecular characterization of the CysLT 1 receptor showed by in situ hybridization, the presence of CysLT 1 receptor messenger RNA (mRNA) in human lung smooth-muscle cells and lung macrophages. We confirmed the results of these in situ hybridization analyses for the CysLT 1 receptor, and produced the first immunohistochemical characterization of the CysLT 1 receptor protein in human lung. The identification of the CysLT 1 receptor in the lung is consistent with the antibronchoconstrictive and antiinflammatory actions of CysLT 1 receptor antagonists. We also report the expression of CysLT 1 receptor mRNA and protein in most peripheral blood eosinophils and pregranulocytic CD34 ϩ cells, and in subsets of monocytes and B lymphocytes.
The cysteinyl leukotrienes (CysLTs), leukotriene (LT)C 4 , LTD 4 , and LTE 4 , are produced by LTC 4 synthase from the precursor leukotriene LTA 4 , which is in turn a product of 5-lipoxygenation of the polyunsaturated fatty acid arachidonic acid (1, 2) . LTC 4 synthase has been shown to be produced by inflammatory cells, and particularly by eosinophils, and the gene for this enzyme is encoded on chromosome 5q13, a locus rich in genes encoding proinflammatory cytokines such as interleukin (IL)-4, IL-5, and IL-13 (3) . CysLTs are the most potent bronchoconstrictors known and have been identified in urine and tissues from patients with a number of respiratory diseases, such as asthma, virus-induced wheezing, and bronchial hyperreactivity (4) (5) (6) (7) . At least two human CysLT receptors have been defined pharmacologically (8) . Most of the biologic activities ascribed to CysLTs, including bronchospasm, plasma exudation, vasoconstriction, mucus secretion, and eosinophil recruitment, are mediated through interaction with the CysLT 1 receptor subtype (9) . The CysLT 1 receptor is also the target of the antiasthmatic CysLT 1 receptor antagonists montelukast (Singulair; Merck & Co., West Point, PA) (10) (11) (12) (13) (14) , zafirlukast (Accolate; Zeneca Pharmaceuticals, Wilmington, DE) (15) , and pranlukast (Onon; SmithKline Beecham, Harlow, UK) (16) .
The complementary DNA (cDNA) for the CysLT 1 receptor has been recently cloned, and encodes a 337-amino acid, G-protein-coupled receptor (GPCR) putatively spanning the 7-transmembrane domain (17, 18) . The major intracellular signaling pathway for activation of the recombinant CysLT 1 receptor is via calcium release (17, 18) . A second CysLT receptor, CysLT 2 , has been described pharmacologically and appears to be implicated in some of the vascular effects of CysLTs (19) . In the human monocytic THP-1 cell, there are at least two signaling pathways activated by CysLTs, which respectively lead to an increase in intracellular calcium that results in activation of mitogen-activated kinase (MAP kinase), and a pertussis toxin-sensitive chemotactic response pathway (20) .
The molecular cloning of the CysLT 1 receptor has allowed investigation of the expression of this target for asthma therapy. In Northern blot analyses of human tissues, the highest level of expression of the CysLT 1 receptor was found in peripheral blood leukocytes, followed by spleen, lung, pancreas, small intestine, and a number of other tissues (17, 18) . Reverse transcription-polymerase chain reaction (RT-PCR) has revealed the mRNA for the receptor in a number of cell lines, including THP-1 cells and the human lymphoblastic U937 cell line (K. R. Lynch, personal communication). RT-PCR showed no difference in overall lung expression of the receptor mRNA between normal and asthmatic individuals (18) . However, since the in situ pattern of the CysLT 1 receptor in human lung showed very confined localization to smooth-muscle cells and some macrophages, detailed in situ hybridization and immunohistochemical comparisons of diseased and normal samples will be needed to address pathologic variation in the expression of the CysLT 1 receptor. To date, there have been no descriptions of the CysLT 1 receptor protein in any tissues or cells. We describe here the distribution of the CysLT 1 receptor protein in smooth-muscle cells of normal human lung and in macrophages and peripheral blood leukocytes.
METHODS

Production of Antisera and Immunoblot Analyses
Recombinant CysLT 1 receptor was expressed in Escherichia coli as a lambda repressor CysLT 1 receptor-histidine-tagged fusion protein (R. Breyer, Vanderbilt University, U.S. Patent #09/293179), and the purified antigen was used to raise the goat anti-CysLT 1 receptor-specific antisera described in these studies. A goat was injected with 0.5 mg of purified recombinant CysLT 1 receptor fusion protein in complete Freund's adjuvant, and received three subsequent booster doses of 0.25 mg of the same antigen in incomplete Freund's adjuvant. The antiserum so obtained was titrated with an enzyme-linked immunosorbent assay (ELISA) against the purified recombinant CysLT 1 receptor, and was shown to specifically recognize the receptor protein at a dilution of ‫ف‬ 1:1,000. For immunoblot analyses, purified recombinant CysLT 1 receptor (8 to 160 ng) was separated by sodium dodecylsulfate-polyacrylamide gel electrophoresis on 4%-to 20%-gradient Novex gels and blotted onto nitrocellulose overnight at 100 mA. Blots were blocked for 1 h in 5% milk in Tris-buffered saline containing 0.1% Tween (pH 7.4) (TTBS). Blots were incubated with immune antisera at a 1:5,000 dilution in 5% milk/TTBS for 60 min, washed three times in TTBS, and incubated with a sheep anti goat second antibody (Amersham, Arlington Heights, IL) at a 1:3,000 dilution in 3% milk/TTBS for 60 min. Blots were washed three times in Tris-buffered saline containing 0.3% Tween-20, rinsed with TBS, and subjected to enhanced chemiluminescence (ECL) detection (Amersham) according to the manufacturer's instructions.
Purification of Peripheral Blood Mononuclear Cells Minus T Cells, T Cells, and Eosinophils
Standard blood-cell purification methods were used to obtain partially purified preparations from normal donors. Peripheral blood mononuclear cells (PBMC) were isolated from buffy-coat preparations by centrifugation over lymphocyte separation medium (LSM) (ICN). T cells were rosetted by the incubation of PBMC with neuraminidase-treated sheep red blood cells (SRBC) and were pelleted through LSM. The SRBC were removed by lysis with ammonium chloride potassium (ACK) lysis buffer (Gibco/BRL, Rockville, MD). T-cell-depleted PBMC accumulated at the interface of the LSM. Eosinophils were prepared from peripheral blood from donors known to have increased peripheral blood eosinophils counts as a result of seasonal allergies, but with no history of asthmatic disease. Erythrocytes were removed by hypotonic lysis of the pelleted cells, followed by negative selection with anti-CD16 microbeads (Miltenyi Biotech, Auburn, CA) according to the manufacturer's instructions. Purity of eosinophil preparations was Ͼ 90%, with some contaminating monocytes and neutrophils. All preparations of cells were either pelleted in 4% paraformaldehyde or were fresh frozen before in situ hybridization or immunohistochemistry.
In Situ Hybridization and Immunohistochemistry
Purified blood cells were prepared for histologic analysis by one of the following two methods: ( 1 ) fresh-frozen cells were rinsed in phosphatebuffered saline (PBS) (Sigma, St. Louis, MO), made with diethylpyrocarbonate-treated water (Eppendorf, Westbury, NY), resuspended in ornithine carbamyltransferase (OCT) solution (Miles, Elkhart, IN), and frozen at Ϫ 20 Њ C; or ( 2 ) cells were pelleted and fixed in 4% paraformaldehyde (Electron Microscopy Sciences, Fort Washington, PA), dehydrated in graded ethanols, and processed to paraffin. Frozen normal lung biopsy samples (National Disease Research Interchange, Philadelphia, PA) or frozen purified cells were embedded in OCT solution, sectioned at 8 m, thaw-mounted onto Superfrost Plus slides (Fisher Scientific, Pittsburgh, PA) and fixed for 30 min in 4% paraformaldehyde. Cells embedded in paraffin were dewaxed, rehydrated, and digested for 10 min in 10 g/ml proteinase K (Boehringer Mannheim, Indianapolis, IN) at room temperature. Oligonucleotide antisense and sense CysLT 1 receptor mRNA probes were prepared, and in situ hybridization was done as previously described (17) . Bound probe was detected with the TSA direct red fluorescence in situ hybridization tyramide amplification kit (NEN Life Sciences, Boston, MA) according to the manufacturer's instructions. Double-label cell identification immunohistochemistry was performed on specimens that showed a fluorescence signal for CysLT 1 receptor mRNA. Cells were rinsed in PBS, blocked with 10% normal donkey serum (Jackson Immunoresearch, West Grove, PA), and incubated for 2 h with the appropriate cell-surface identification marker according to the manufacturer's recommended procedures. Identification marker antisera used on PBMC preparations were CD19 (Pharmingen, San Diego, CA), a marker for B-precursor and B cells; CD18 (Pharmingen), a marker for monocytes and granulocytes; CD34 (Pharmingen), a marker for pluripotent hematopoietic stem cells; LN5 (Zymed, San Francisco, CA), a macrophage marker; CD14 (Serotec, Oxford, UK), a marker for monocytes, granulocytes, and dendritic cells; and an antiserum to the IL-5 receptor ␤ -subunit (R&D Systems, Inc., Minneapolis, MN).
Identification-marker antisera used on T cells were CD4 (Dako, Carpinteria, CA) and CD8 (Dako). The identification marker for eosinophils was the CCR3 receptor, detected with an antiserum from Bruce Daugherty (Merck Research Labs) (21) . In the last-named case, immunohistochemistry was done on saponin-treated cells with extensive blocking. Immune-specific signal was detected with the appropriate fluorescein isothiocyanate-labeled donkey secondary antisera (Jackson Immunoresearch). Immune-complexed sections were rinsed and counterstained with DAPI (Molecular Probes, Eugene, OR). Images were acquired, processed, and quantified with a Nikon E1000 microscope (Nikon, Tokyo, Japan), Micromax CCD camera (Princeton Instruments, San Diego, CA), and Metamorph imaging program (Universal Imaging, West Chester, PA).
RESULTS
In order to investigate the distribution of CysLT 1 receptor mRNA and protein in human lung and peripheral blood cells, we made a specific oligonucleotide probe, 5 Ј -GAACATAAT-AGACCACACGGAGAGGCAGTG-3 Ј (antisense) and antiserum (17) . The oligonucleotide antisense probe had previously been shown to recognize CysLT 1 receptor mRNA in human lung muscle cells and macrophages (17) . The antiserum, first described in the present study, showed specific recognition of the purified CysLT 1 receptor on immunoblot analysis ( Figure  1A ). We were unable to detect the receptor in immunoblot analyses of lung tissue or COS cells transfected with the CysLT 1 receptor membrane fractions (data not shown). We calculated from the expression levels of the CysLT 1 receptor in human lung or in COS CysLT 1 receptor-transfected membranes (both having about 50 fmol/mg protein), and from the sensitivity of the antiserum to recombinant receptor protein, that unless the receptor was concentrated in some fashion, its concentration would be below the detection limits of Western blot analysis. The monomeric recombinant CysLT 1 receptor had a molecular weight of approximately 42 kD, but much larger amounts of dimerized and oligomerized receptors were observed in these preparations even in the presence of the denaturing gel detergents ( Figure 1A) . No CysLT 1 receptor signal was seen with antiserum adsorbed with 10 g/ml purified CysLT 1 recombinant receptor or with control, nonimmune goat antisera (Figures 1B and 1C) .
Since immunohistochemistry is more sensitive than immunoblot analysis, we conducted immunostaining on COS cells transiently transfected with the CysLT 1 receptor and with COS cells alone, and compared the results (Figures 1D through  1G ). COS cells alone showed no signal with the antisera (Figure 1D) , in contrast to the positive staining observed in CysLT 1 receptor-transfected COS cells ( Figure 1E ). No signal was seen in the same sample with normal goat serum ( Figure  1G ), and the positive staining for CysLT 1 receptor on COS CysLT 1 -transfected cells was eliminated by preadsorption with recombinant CysLT 1 receptor protein ( Figure 1F) .
In normal human lung, CysLT 1 receptor mRNA was expressed in smooth-muscle fibers (Figures 2A and 2B) , in accord with our previously reported findings (17) . Using the specific CysLT 1 antiserum, we found that CysLT 1 receptor protein coincided with expression of the receptor mRNA ( Figure 2C ). The specificity of the immunohistochemical identification of the CysLT 1 receptor protein was shown by the absence of signal after preincubation of the antiserum with recombinant CysLT 1 protein ( Figure 2D ). In addition, CysLT 1 receptor mRNA and protein were identified in human lung interstitial macrophages by colocalization with LN5 panmacrophage antigen ( Figures 2E through 2I) . At higher magnification, the CysLT 1 receptor protein signal appeared to be punctated (Figures 2H and 2I) . The intimate spatial relationship of a lung macrophage and a smooth-muscle cell, both expressing the CysLT 1 receptor, is shown in Figures 2H and 2I .
Because CysLTs were observed in lung macrophages, and have been suggested to contribute significantly to the inflammatory components of asthma (22), we investigated the expression of the CysLT 1 receptor in human peripheral blood cells. In PBMC from which T cells had been removed, we observed CysLT 1 receptor mRNA and protein in about 20% of the total cell population (Figures 3A through 3D ; Table 1 ). Subsets of CysLT 1 -positive PBMC coexpressed CD14 (Fig-ures 4A through 4C ) and CD19 ( Figures 4D through 4F ). These antigenic markers have been used previously to identify monocytic and B-lymphocytic cells, respectively (23, 24) . In the PBMC population, immunoreactive labeling of the CysLT 1 receptor appeared in clusters ( Figures 3C and 4A) . The punctate appearance of the CysLT 1 receptor protein in peripheral blood cells may reflect oligomerization of the receptor and/or membrane compartmentalization with other proteins or lipids, as has been shown for the chemotactic formyl-met-leu-phe receptor (25) . In the PBMC preparation, all of the rarely found pregranulocytic CD34 ϩ -staining cells ( Ͻ 1 per 1,000 cells) (25) coexpressed the CysLT 1 receptor (Figures 4G through 4I) . The CysLT 1 receptor was also found to be coexpressed with some, but not all, cells expressing the IL-5 receptor ␤ -subunit ( Figures 4J through 4L) .
Because eosinophils have been suggested to exacerbate inflammation in asthma, and CysLTs have been shown to be potent chemoattractants for eosinophils both in vitro and in vivo (27-29), we next investigated whether the CysLT 1 receptor is expressed on human peripheral blood eosinophils. In purified populations of eosinophils from hypereosinophilic but nonasthmatic subjects, we observed specific expression of CysLT 1 receptor mRNA and protein ( Figures 5A and 5D ). The majority of these cells also showed immunoreactivity for the CCR3 receptor, a beta-chemokine receptor expressed on eosinophils (21) (Figures 5D through 5F ; Table 1) .
In a population of T cells purified from our samples of peripheral blood cells from nonasthmatic subjects, the CysLT 1 receptor mRNA or protein was rarely present, in contrast to the abundant CysLT 1 receptor expression demonstrated on Definition of abbreviations: CysLT ϭ cysteinyl leukotriene; mRNA ϭ messenger RNA; PBMC ϭ peripheral blood mononuclear cells.
* Represents percent derived from at least 100 cells counted in each cell population. Table 1 ). We were able to demonstrate both CD4 ϩ and CD8 ϩ helper T cells in this preparation, and neither of these subsets of T cells expressed the CysLT 1 receptor (Figures 6A through 6D) . CysLT 1 receptor expression may be upregulated in lymphocytes from asthmatic subjects. Quantification of the expression of CysLT 1 receptor mRNA and protein in populations of normal human peripheral blood cells is shown in Table 1 .
DISCUSSION
We report here the immunohistochemical identification of the CysLT 1 receptor protein in normal human lung and normal human peripheral blood cells, in accord with the in situ expression of CysLT 1 mRNA in human lung smooth-muscle cells and macrophages demonstrated by the molecular cloning of the CysLT 1 receptor (17) . With a panel of peripheral blood cell markers, we further found that the receptor is expressed in cells of particular relevance to asthma and atopy, namely eosinophils, monocytes/macrophages, and B lymphocytes, and in CD34
ϩ granulocytic precursor cells. The demonstration of the CysLT 1 receptor on eosinophils concurs with observations that CysLT 1 receptor antagonists inhibit eosinophil chemotaxis and airway inflammation (30, 31) , and that CysLTs partly mediate eotaxin-induced bronchial hyperresponsiveness and eosinophilia in IL-5-transgenic mice (32) . The expression of the CysLT 1 receptor on monocytes is consistent with previous CysLT 1 receptor binding characterizations and with functional activation studies of premyelocytic HL-60 and THP-1 cells (9) . Ours is the first demonstration of the CysLT 1 receptor on B lymphocytes, although the receptor has been well characterized on the lymphoblastoid U937 cell line, and B lymphocytes have been shown to produce leukotrienes under some conditions (9, 33) . The demonstration of the CysLT 1 receptor on CD34 ϩ pregranulocytic cells is intriguing, given the detection of increased numbers of CD34 ϩ cells in bronchial biopsy specimens from atopic asthmatic and atopic nonasthmatic subjects (34) . The receptor was neither in peripheral polymorphonuclear leukocytes nor in the majority of T cells, in accord with most reports in the literature (9) .
The expression of the CysLT receptor on eosinophils and monocytes, both of which are cell types capable of synthesizing CysLTs, suggests that both autocrine and paracrine activation may occur after stimulation by the appropriate inflammatory signal. The expression of the CysLT 1 receptor on pregranulocytic CD34 ϩ cells raises the possibility that under some conditions, CysLTs may influence the differentiation pathway of these cells. A subset of cells expressing the IL-5 receptor ␤-chain (common to the IL-5, IL-3, and granulocyte-macrophage colony-stimulating factor receptors) also coexpressed the CysLT 1 receptor. We hypothesize that CysLTs prime the maturation of CD34 ϩ precursor cells to eosinophils, monocytes/ macrophages, and subsets of lymphocytic cells in the peripheral blood compartment (Figure 7) . During an asthmatic exacerbation, CysLTs produced in the lung by eosinophils and macrophages (and also by mast cells in an atopic patient) may activate bronchial smooth-muscle CysLT 1 receptors, producing bronchoconstriction. In addition, the CysLTs may act in an autocrine and paracrine fashion on CysLT 1 receptors on interstitial precursor granulocytes, eosinophils, and macrophages, thereby amplifying both the immediate lung damage and expanding the populations of inflammatory cells in the lung (Figure 7) . Such a positive feedback mechanism may in part explain the clinically observed progressively refractory bronchospasm and inflammation that characterize asthma.
Our characterization of the expression of the CysLT 1 receptor in the lung is consistent with that in many pharmacologic and clinical studies of the effects of CysLTs and specific CysLT 1 receptor antagonists. In addition, the localization of the CysLT 1 receptor on subsets of B-lymphocytic (CD19 ϩ hemopoietic progenitor cell may be primed to differentiate to mature blood cells by a variety of cytokines, through their appropriate receptors, and by CysLT activation of the CysLT 1 receptor.
